The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose tumors had mutations in the MAPK cell-signaling pathway, according to data from a phase I clinical ...
Dec 15, 2017
0
6
Older women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase inhibitors 4 and 6 (CDK4/6) achieved progression-free survival at a rate similar to that ...
Dec 8, 2017
0
1
Younger breast cancer patients who underwent axillary lymph node dissection were more likely to experience arm swelling and decreased range of arm motion than patients who received sentinel lymph node biopsies, according ...
Dec 8, 2017
0
1
Postmenopausal women who lose weight may have a significantly reduced chance of developing breast cancer, according to data presented at the 2017 San Antonio Breast Cancer Symposium, held Dec. 5–9.
Dec 8, 2017
0
3
Postmenopausal women with hormone-receptor positive (HR-positive) breast cancer who took the aromatase inhibitor anastrozole for two years after an initial five years of adjuvant endocrine therapy received an equal benefit ...
Dec 7, 2017
0
2
Meta-analysis of individual patient data from five randomized clinical trials provided a high level of evidence that treatment with a gonadotropin-releasing hormone analog (GnRHa) could safely and effectively protect ovarian ...
Dec 7, 2017
0
3
Acupuncture significantly reduced joint pain for postmenopausal women with early-stage breast cancer receiving treatment with an aromatase inhibitor compared with both sham acupuncture and no treatment, according to data ...
Dec 7, 2017
0
10
Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry ...
Dec 6, 2017
0
1
Increasing the dose intensity of chemotherapy by either shortening the intervals between the cycles or by sequential administration instead of concurrent administration of the drugs reduced the risk of early-stage breast ...
Dec 6, 2017
0
1
Differences in the genes expressed in non-small cell lung cancers (NSCLCs) from some African-Americans and European-Americans suggest that there are racial differences in the biology of NSCLC, which could have clinical relevance.
Dec 1, 2017
0
0
